Among the molecules targeting the E3s and DUBs of the PTEN/AKT pathway [154], indole-3-carbinol, a natural inhibitor of NEDD4 and WWP1, induces PTEN upregulation and has been investigated in clinical trials for the treatment of breast (NCT00033345) and prostate (NCT00607932) cancer, although the results of these trials have not been reported on ClinicalTrials.gov. This evidence concerns the gene PTEN and cancer.